Loading…

Savara, Inc.SVRACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare lung disease.

Momentum neutral 41
Mkt cap
$1.04B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$14.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · USD$4.72
1D+5.4%
1W-5.4%
1M-0.8%
3M-14.0%
6M-7.1%
YTD-21.7%
1Y+12.4%
ATR %6.5%
Beta1.35
52w lowhigh32.6% off high

What Savara does

Clinical-stage biotech developing inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare lung disease.

Has no product on sale, so it earns no sales; development is funded by money raised from investors. Its only late-stage drug is aimed at a rare disease, so the company's value depends on regulators approving that one drug and then on selling to a small patient group.

Products and services

  • Molgramostim (aPAP)

Where it sits in the supply chain

  • Biopharma R&D
  • Inhaled GM-CSF drug development
  • Rare lung-disease clinical trials

What could go right

  • Approval addressing unmet need (no approved therapy)
  • Orphan-drug pricing potential

What could go wrong

  • Regulatory/trial delay risk
  • Small addressable rare-disease population

Moat: narrow (IP / patents, regulatory licence). First potential approved therapy for a rare disease with no current approved treatment.

Headquarters: Langhorne, Pennsylvania, US · Employees: 70

Named competitors

Savara at a glance

Size Savara (SVRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.04B, the 2206th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.72 on 18 Nov 2026.

Performance Over six months the shares fell 7.1%, against -10.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.

Short interest Short interest is 15.7% of the free float (30 Oct 2026).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026SVRA 93Peer median 92
Six months, rebased to 100: Savara against the median of its 20 peers (local-currency closes).

Savara financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$301,000-$245,000-$275,000-$175,000-$167,000
EBITDA-$157M-$123M-$103M-$59.8M-$38.7M
Net income-$153M-$119M-$95.9M-$54.7M-$38.1M
Free cash flow-$131M-$101M-$89.1M-$51.4M-$34.6M
Capital expenditure$631,000$22,000$25,000$296,000$9,000
Total debt$30.4M$29.9M$26.8M$26.7M$26.2M

Quarterly statements and history in the cockpit →

Savara competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%-10%0%BSLN002737600789BLUEJET455319526885133004973007020006504887OMER688091600812605116688710MEDCLPYCAARTIPHARMSVRA6-month return →1-month return →
Up and to the right = strong over both horizons. Savara is the large dot.

Savara competitors and peer comparison

Head to head with its named competitors (SVRA vs INSM)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Savara SVRA$1.04B-7%n/an/an/an/a
Insmed INSM$26.3B+3%+240%-42%17.0×n/a

How Savara compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Savara against its 20 peers (data as of 18 Nov 2026)
MeasureSVRAPeer medianRank in peer set
1-month return-0.8%-5.9%7th highest of 21
6-month return-7.1%-10.6%9th highest of 21
Distance from 52-week high-32.6%-31.7%9th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%3.2×-5.6%+12.7%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%1.7×-6.5%-7.7%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%1.5×2.5%+6.5%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%8.1×40.8%+13.8%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%1.2×-0.3%+12.1%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%3.0×n/an/a
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%4.2×4.4%+7.7%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%4.0×7.5%-4.5%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%2.3×4.3%+3.5%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%0.9×-10.7%-7.0%
SAWAI 4887.TJapan$1.01B-18%+2%9%1.3×n/an/a
Omeros OMERUnited States$1.08B+24%n/a-56%17.3×n/an/a
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%19.3×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%2.4×1.0%-4.2%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%4.2×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%5.2×12.7%+19.4%
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%49.6×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%1.4×2.3%+1.8%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%4.7×n/an/a

Questions

Who are Savara's main competitors?
Named competitors: Insmed (INSM). The cockpit's measured peer set (industry) also includes Basilea Pharmaceutica (BSLN.SW), Sunflower Pharmaceutical (002737.SZ), Shandong Lukang Pharmaceutical (600789.SS), Blue Jet Healthcare (BLUEJET.NS), Towa Pharmaceutical (4553.T), Everest Medicines (1952.HK).
How has Savara stock performed?
Over six months to 18 Nov 2026 the shares returned -7.1% against -10.6% for the median peer; over one year +12.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.